Kaigene, Inc.
StreetZero Signal 82
About Kaigene, Inc.
Kaigene Inc. is a biotechnology company that develops innovative antibody therapeutics and fusion proteins to address unmet clinical needs in rare autoimmune diseases. Founded in 2022 and headquartered in Rockville, Maryland, the company focuses on targeted degradation of pathogenic antibodies through platforms such as PDEG. It maintains operations in the U.S. with a primary website at kaigene.com.
LATEST FUNDINGPrivate Placement
$55.0M
Announced 2026-10-14
TOTAL RAISED$31.5M
IN THE NEWS
- 🔗 Kaigene Inc. Valuation & Funding History | Caplight
- 🔗 Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
- 🔗 Kaigene Licenses KG006 to Taisho in Japan | Contract Pharma
- 🔗 Kaigene, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
- 🔗 Kaigene, Inc
EMPLOYEES11-50
FOUNDED2022
HQRockville, MD, United States
Industry
Biotechnology
Tags
BiotechnologyAntibody TherapeuticsAutoimmune Diseases
Key highlights
- Raised $54,958,229 in private placement as biotechnology company in Rockville, MD.
- Secured exclusive licensing deal with Celltrion for KG006 with $8M upfront and up to $736M milestones.
- Licensed KG006 to Taisho for Japan with $5M upfront and up to $351M+ in milestones and royalties.
- Operates with focus on antibody discovery engines for severe autoimmune diseases since 2022.
Ask StreetZero about Kaigene, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account